1
Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy
Condition(s):Non-small Cell Lung Cancer; Vomiting; Nausea; EmesisLast Updated:April 3, 2015Unknown status
Fosaprepitant: 161 Clinical Trials, Page 1 of 17
Hide Studies Not Open or Pending
2
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
Condition(s):Chemotherapy-induced Nausea and VomitingLast Updated:June 7, 2018Terminated
3
Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic Drugs
Condition(s):Chemotherapy Induced Nausea and Vomiting Pediatric Cancer PatientsLast Updated:February 9, 2022Not yet recruiting
4
Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients
Condition(s):Chemotherapy Induced Nausea and Vomiting; Pediatric Cancer PatientsLast Updated:May 10, 2021Not yet recruiting
5
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
Condition(s):Chemotherapy-induced Nausea and VomitingLast Updated:September 23, 2021Completed
6
Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients
Condition(s):Pediatric CancerLast Updated:September 2, 2021Not yet recruiting
7
Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
Condition(s):Nasopharyngeal CarcinomaLast Updated:November 19, 2020Recruiting
8
Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study
Condition(s):Solid Tumor Patients Receiving High Emetic Risk Multi-day ChemotherapyLast Updated:September 2, 2020Not yet recruiting
9
Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia
Condition(s):Postoperative NauseaLast Updated:February 11, 2021Active, not recruiting
10
Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy
Condition(s):Gastrointestinal Cancer; Nausea Post ChemotherapyLast Updated:April 8, 2021Completed